Specific inhibition of GCNT3 by talniflumate, an orally available, small-molecule inhibitor and a muco-regulator, blocks mucous overproduction in patients with chronic respiratory diseases, and reduces cystic fibrosis [14]. The gene discussed is GCNT3; the disease is cystic fibrosis.